Evidence map›Paper›PMID 32377899›Full record

ArticleApplied microbiology and biotechnology2020

Histoplasma capsulatum 100-kilodalton antigen: recombinant production, characterization, and evaluation of its possible application in the diagnosis of histoplasmosis.

María A Toscanini, Daniel González Maglio, Paula Capece, Gladys Posse, Cristina A Iovannitti, Alejandro D Nusblat, María L Cuestas

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Diagnosis of histoplasmosis: current status and perspectives.Applied microbiology and biotechnology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

María A ToscaniniFacultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología (NANOBIOTEC), Universidad de Buenos Aires, Buenos Aires, Argentina.
Daniel González MaglioFacultad de Farmacia y Bioquímica. Cátedra de Inmunología, Universidad de Buenos Aires, Buenos Aires, Argentina.
Paula CapeceLaboratorio de Micología. Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina.
Gladys PosseLaboratorio de Micología. Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina.
Cristina A IovannittiInstituto de Investigaciones en Microbiología y Parasitología Médica (IMPaM), Universidad de Buenos Aires. CONICET, Buenos Aires, Argentina.
Alejandro D NusblatFacultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología (NANOBIOTEC), Universidad de Buenos Aires, Buenos Aires, Argentina.
María L CuestasInstituto de Investigaciones en Microbiología y Parasitología Médica (IMPaM), Universidad de Buenos Aires. CONICET, Buenos Aires, Argentina. marilucuestas@gmail.com.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARHospital Posadas · ARInstituto de Biotecnología y Biología Molecular · AR

Funding

Secretaría de Ciencia y Técnica, Universidad de Buenos Aires Grant UBACyT 20020130200222BA
6 · The paper itself

Abstract

The goal of the present work was to develop a novel reagent with potential for histoplasmosis diagnosis. For this purpose, the genetic sequence of the 100 kDa protein of Histoplasma capsulatum (Hcp100) was cloned and expressed as a secretory protein in Pichia pastoris. After optimizing the culture conditions and purifying by immobilized metal ion affinity chromatography, the highest yield of Hcp100 reached approximately 1.3 mg/l with > 90% purity in shake flasks using basal salt medium supplemented with casamino acids after 72 h of methanol induction. To investigate its potential for diagnosis, its detection in urine samples using specific polyclonal antibodies as reagent was evaluated by dot blot in 6 patients with progressive disseminated histoplasmosis (PDH), of whom all had AIDS. Antigen was detected in urine from all 6 (100%) PDH patients. Urine samples from a pool of 20 healthy individuals did not react with the anti-Hcp100 antibodies. The dot blot assay performed in this study provides preliminary data of a simple technology that can be performed in medical institutions with limited resources to facilitate the rapid diagnosis of histoplasmosis, particularly the disseminated forms. Hence, use of these assays may provide a rapid diagnostic tool of PDH in endemic areas for histoplasmosis where PDH-related mortality is high, hastening treatment and improving patient survival. Finally, this novel antigen and its specific antibodies may provide an alternative diagnostic reagent to the largely unknown and poorly characterized polysaccharide antigens (HPA, galactomannan, histoplasmin) frequently used in the diagnostic tests. KEY POINTS: Few antigens are used as laboratory tools for the immunodiagnosis of histoplasmosis. P. pastoris was an excellent system for recombinant Hcp100 expression. Maximum expression levels of rHcp100 were achieved in BSM with 1% casamino acids. Dot blot assays with anti-rHcp100 antisera can be successfully used for diagnosing PHD.

Indexed as

AnimalsAntibodies, FungalAntigens, FungalFungal ProteinsHistoplasmaHistoplasmosisHumansImmunologic TestsMiceRabbitsRecombinant ProteinsSaccharomycetalesAntibodies, FungalAntigens, FungalFungal ProteinsHcp100 protein, Histoplasma capsulatumRecombinant ProteinsAntibodies anti-rHcp100Casamino acidsDiagnosisHistoplasma capsulatumPichia pastorisRecombinant Hcp100

Identifiers

PMID32377899
OpenAlexW3023067119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.